AU2004247025B8 - Fusion proteins for the treatment of CNS - Google Patents

Fusion proteins for the treatment of CNS Download PDF

Info

Publication number
AU2004247025B8
AU2004247025B8 AU2004247025A AU2004247025A AU2004247025B8 AU 2004247025 B8 AU2004247025 B8 AU 2004247025B8 AU 2004247025 A AU2004247025 A AU 2004247025A AU 2004247025 A AU2004247025 A AU 2004247025A AU 2004247025 B8 AU2004247025 B8 AU 2004247025B8
Authority
AU
Australia
Prior art keywords
chondroitinase
enzyme
protein
agent
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004247025A
Other languages
English (en)
Other versions
AU2004247025B2 (en
AU2004247025A1 (en
Inventor
Anthony O. Caggiano
Elliott A. Gruskin
Jennifer Iaci
Gargi Roy
Michael P. Zimber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acorda Therapeutics Inc
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of AU2004247025A1 publication Critical patent/AU2004247025A1/en
Publication of AU2004247025B2 publication Critical patent/AU2004247025B2/en
Application granted granted Critical
Publication of AU2004247025B8 publication Critical patent/AU2004247025B8/en
Priority to AU2011224070A priority Critical patent/AU2011224070B2/en
Priority to AU2014265113A priority patent/AU2014265113B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2004247025A 2003-05-16 2004-05-17 Fusion proteins for the treatment of CNS Ceased AU2004247025B8 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2011224070A AU2011224070B2 (en) 2003-05-16 2011-09-15 Fusion proteins for the treatment of CNS
AU2014265113A AU2014265113B2 (en) 2003-05-16 2014-11-21 Fusion proteins for the treatment of cns

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US47123903P 2003-05-16 2003-05-16
US47123603P 2003-05-16 2003-05-16
US47124003P 2003-05-16 2003-05-16
US47130003P 2003-05-16 2003-05-16
US60/471,239 2003-05-16
US60/471,236 2003-05-16
US60/471,300 2003-05-16
US60/471,240 2003-05-16
US47437203P 2003-05-29 2003-05-29
US60/474,372 2003-05-29
PCT/US2004/015661 WO2004110359A2 (en) 2003-05-16 2004-05-17 Fusion proteins for the treatment of cns

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2011224070A Division AU2011224070B2 (en) 2003-05-16 2011-09-15 Fusion proteins for the treatment of CNS

Publications (3)

Publication Number Publication Date
AU2004247025A1 AU2004247025A1 (en) 2004-12-23
AU2004247025B2 AU2004247025B2 (en) 2011-06-23
AU2004247025B8 true AU2004247025B8 (en) 2011-06-30

Family

ID=33556640

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004247025A Ceased AU2004247025B8 (en) 2003-05-16 2004-05-17 Fusion proteins for the treatment of CNS

Country Status (7)

Country Link
EP (3) EP3210999B1 (enExample)
JP (5) JP5399612B2 (enExample)
AU (1) AU2004247025B8 (enExample)
CA (1) CA2525782C (enExample)
ES (1) ES2831031T3 (enExample)
MX (2) MX351062B (enExample)
WO (1) WO2004110359A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8785606B2 (en) 2002-05-04 2014-07-22 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
US9102930B2 (en) 2006-10-10 2015-08-11 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666852B2 (en) * 2002-04-22 2010-02-23 Agenta Biotechnologies, Inc. Wound and cutaneous injury healing with a nucleic acid encoding a proteoglycan polypeptide
EP3211084B1 (en) 2003-05-16 2019-03-27 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of cns
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
MXPA06013345A (es) 2004-05-18 2008-10-31 Acorda Therapeutics Inc Metodos para purificar condrointinasa y sus formulaciones estables.
JP5189985B2 (ja) 2005-09-26 2013-04-24 アコーダ セラピューティクス、インク． コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法
US8968728B2 (en) * 2006-05-12 2015-03-03 Bharat Biotech International Limited Chimeric fusion proteins
WO2007136042A1 (ja) 2006-05-19 2007-11-29 Aichi Prefecture 脳損傷改善剤
ES2437110T3 (es) * 2006-11-14 2014-01-08 Genentech, Inc. Moduladores de la regeneración neuronal
WO2008149428A1 (ja) * 2007-06-05 2008-12-11 Glycoscience Laboratories, Inc. 自己免疫疾患、炎症及び神経疾患の治療剤及び予防剤
AU2015200220A1 (en) * 2008-02-29 2015-02-12 Acorda Therapeutics, Inc. Method for achieving desired glial growth factor 2 plasma levels
WO2009108390A2 (en) * 2008-02-29 2009-09-03 Acorda Therapeutics, Inc. Method for achieving desired glial growth factor 2 plasma levels
EP2603221A4 (en) * 2010-08-13 2014-02-26 Univ Georgetown GGF2 AND METHOD FOR ITS APPLICATION
EP2756849B1 (en) * 2011-09-15 2016-03-16 Seikagaku Corporation Skeletal muscle regeneration promoter
GB201322396D0 (en) 2013-12-18 2014-02-05 Univ Nottingham Transduction
EP3475418A4 (en) * 2016-06-28 2020-03-04 Alma Mater Studiorum -Universita' di Bologna TATK-CDKL5 FUSION PROTEINS, COMPOSITIONS, FORMULATIONS AND THEIR USE
US11396529B2 (en) 2020-11-12 2022-07-26 National Sun Yat-Sen University Isolated peptide, anti-cancer medicinal composition including the same and method of specifically reducing or inhibiting activities of cancer cells using the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052149A1 (en) * 1999-03-02 2000-09-08 Insight Strategy & Marketing Ltd. Introducing a biological material into a patient
WO2002055684A2 (en) * 2001-01-09 2002-07-18 Univ Iowa Res Found Synthetic proteins containing a protein transduction domain
WO2002083179A2 (en) * 2001-04-12 2002-10-24 Bioaxone Therapeutique Inc. Fusion proteins

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
AU697156B2 (en) * 1993-04-23 1998-10-01 American Cyanamid Company Cloning and expression of the chondroitinase I and II genes from (p. vulgaris)
AU1176595A (en) * 1993-11-12 1995-05-29 International Technology Management Associates, Ltd. Methods of repairing connective tissues
JPH07316068A (ja) * 1994-05-25 1995-12-05 Canji Inc 腫瘍サプレッサー融合タンパク質
GB9622500D0 (en) * 1996-10-29 1997-01-08 Oxford Biomedica Ltd Therapeutic gene
US6171575B1 (en) * 1998-04-06 2001-01-09 Shinichi Okuyama Method of radioisotopic assessment of the integrity and function of the nose-brain barrier
AU7497000A (en) * 1999-02-28 2000-11-14 Washington University Novel transduction molecules and methods for using same
CA2361292C (en) * 1999-03-16 2012-05-29 Edward A. Berger A novel chimeric protein for prevention and treatment of hiv infection
SE9901428D0 (sv) * 1999-04-21 1999-04-21 Karolinska Innovations Ab Amphibodies
CN101433715B (zh) * 1999-06-08 2013-04-17 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
CA2393186A1 (en) * 1999-12-02 2001-06-07 Ibex Technologies, Inc. Attenuation of fibroblast proliferation
BR0211888A (pt) * 2001-08-13 2004-08-24 Univ Florida Res Foudantion In Materiais e métodos para promoção de reparo de tecido nervoso
GB0205022D0 (en) * 2002-03-04 2002-04-17 Univ Cambridge Tech Materials and methods for the treatment of cns damage
WO2003100031A2 (en) * 2002-05-20 2003-12-04 Board Of Regents, The University Of Texas System Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues
AU2003265561A1 (en) * 2002-08-15 2004-03-03 Acorda Therapeutics, Inc. Chimeric protein

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052149A1 (en) * 1999-03-02 2000-09-08 Insight Strategy & Marketing Ltd. Introducing a biological material into a patient
WO2002055684A2 (en) * 2001-01-09 2002-07-18 Univ Iowa Res Found Synthetic proteins containing a protein transduction domain
WO2002083179A2 (en) * 2001-04-12 2002-10-24 Bioaxone Therapeutique Inc. Fusion proteins

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8785606B2 (en) 2002-05-04 2014-07-22 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
US9468671B2 (en) 2002-05-04 2016-10-18 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
US9956273B2 (en) 2002-05-04 2018-05-01 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
US9102930B2 (en) 2006-10-10 2015-08-11 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
US9410141B2 (en) 2006-10-10 2016-08-09 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants

Also Published As

Publication number Publication date
CA2525782A1 (en) 2004-12-23
JP5399612B2 (ja) 2014-01-29
JP2013049677A (ja) 2013-03-14
JP5656314B2 (ja) 2015-01-21
ES2831031T3 (es) 2021-06-07
WO2004110359A9 (en) 2006-02-16
MXPA05012306A (es) 2006-04-18
AU2004247025B2 (en) 2011-06-23
EP2354155A2 (en) 2011-08-10
EP1646353A2 (en) 2006-04-19
JP2020111578A (ja) 2020-07-27
MX351062B (es) 2017-09-29
JP2017125035A (ja) 2017-07-20
JP6141571B2 (ja) 2017-07-12
EP3210999B1 (en) 2020-08-26
WO2004110359A2 (en) 2004-12-23
JP6913428B2 (ja) 2021-08-04
WO2004110359A3 (en) 2006-08-17
EP2354155A3 (en) 2011-09-07
JP2007516229A (ja) 2007-06-21
EP2354155B1 (en) 2017-05-03
CA2525782C (en) 2019-02-05
EP3210999A1 (en) 2017-08-30
AU2004247025A1 (en) 2004-12-23
JP2014221793A (ja) 2014-11-27
EP1646353A4 (en) 2008-06-04

Similar Documents

Publication Publication Date Title
US8906363B2 (en) Fusion proteins for the treatment of CNS
JP5656314B2 (ja) Ｃｎｓを治療するための融合タンパク質
JP2007516229A5 (enExample)
AU2014265113B2 (en) Fusion proteins for the treatment of cns
ES2638819T3 (es) Proteínas de fusión para el tratamiento del SNC
AU2016204464A1 (en) Proteoglycan degrading mutants for treatment of cns
CA3025063A1 (en) Proteoglycan degrading mutants for treatment of cns
AU2013201097A1 (en) Proteoglycan degrading mutants for treatment of cns

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 25, NO 24, PAGE(S) 3071 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME ACORDA THERAPEUTICS, INC., APPLICATION NO. 2004247025, UNDER INID (31) INSERT 60/471,240, UNDER INID (32) INSERT 16 MAY 2003, UNDER INID (33) INSERT US

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired